Clinical trial
A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression
NCT02512237 is registered in ClinicalTrials.gov with Zhejiang Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression
- Lead sponsor
- Zhejiang Medicine Co., Ltd.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- March 31, 2016
- Completion date
- January 31, 2017
- Enrollment
- 9 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.